Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
Meta Expands AI Training With Employee Activity Tracking Tools 
U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
EXTON, Pa., May 17, 2017 -- Fibrocell Science, Inc. (NASDAQ:FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today announced that John Maslowski, Chief Executive Officer, will present at the inaugural Cell & Gene Exchange 2017 on Monday, May 22 at 2:00 pm EDT at the Ronald Reagan Building in Washington, D.C. In addition, Mr. Maslowski will participate in a roundtable discussion, “Best Practices for Partnering with Disease Foundations and Patient Groups,” on Monday, May 22 at 3:15 p.m. EDT.
A live webcast of Mr. Maslowski’s presentation and the roundtable discussion will be available under the investor relations section of Fibrocell’s website at www.fibrocell.com/investors/events and archived for 30 days.
Co-produced by the Alliance for Regenerative Medicine and the EBD Group and held in partnership with Global Genes, this event is the only partnering conference that brings together the regulatory, business and patient advocacy communities across the cell and gene therapy sectors.
About Fibrocell
Fibrocell is an autologous cell and gene therapy company translating personalized biologics into medical breakthroughs for diseases affecting the skin and connective tissue. Fibrocell’s most advanced product candidate, FCX-007, is the subject of a Phase 1/2 clinical trial for the treatment of recessive dystrophic epidermolysis bullosa (RDEB). Fibrocell is in pre-clinical development of FCX-013, its product candidate for the treatment of linear scleroderma. Fibrocell’s gene therapy portfolio is being developed in collaboration with Intrexon Corporation (NYSE:XON), a leader in synthetic biology. For more information, visit http://www.fibrocell.com or follow Fibrocell on Twitter at @Fibrocell.
Trademarks
Fibrocell, the Fibrocell logo and Fibrocell Science are trademarks of Fibrocell Science, Inc. and/or its affiliates. All other names may be trademarks of their respective owners.
Investor & Media Relations Contact: Karen Casey 484.713.6133 [email protected]
